Kemnay Advisory Services’s Crinetics Pharmaceuticals CRNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$35.1K Buy
938
+89
+10% +$3.31K ﹤0.01% 423
2026
Q1
$30.8K Buy
849
+615
+263% +$27.5K 0.01% 428
2025
Q4
$10.9K Buy
+234
New +$10.4K ﹤0.01% 726

Other funds holding CRNX

Kemnay Advisory Services's CRNX Position: Q2 2026 in Review

Kemnay Advisory Services increased its Crinetics Pharmaceuticals (CRNX) stake by 10% in Q2 2026, buying an estimated $3.31K and bringing the position to 938 shares worth $35.1K. The position accounts for ﹤0.01% of the portfolio, ranked #423.

Kemnay Advisory Services first reported a position in CRNX in Q4 2025 and has held it in 3 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Kemnay Advisory Services held 938 shares of Crinetics Pharmaceuticals worth $35.1K as of Q2 2026.
  • Kemnay Advisory Services bought 89 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $3.31K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Kemnay Advisory Services's portfolio in Q2 2026, its #423 holding.
  • Kemnay Advisory Services first reported a position in Crinetics Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Kemnay Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.